IMCR News and Press, Immunocore Holdings plc From 01/04/23

Immunocore to present at the 41 st Annual J . P . Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company ...

Summary Clinical trial momentum within the Melanoma diagnostics and treatment paradigm is gaining steam. Immunocore Holdings plc presents with unique exposure for investors to position at the treatment end of the spectrum. Recent advancements in its investigational compounds are wel...

Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 15 December 20...

Immunocore p resents ovarian cancer expansion d ata for ImmTAC ® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers , with vast majority of patients having zero or very low MAGE-A4 expression ...

Immunocore and Gadeta A nnounce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for S olid Tumors Gamma delta TCRs off er potential to address large number of patients without HLA restrict ion...

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the deve...

Immunocore presents new biomarker analysis for KIMMTRAK ( tebentafusp -tebn ) in metastatic uveal melanoma at the SITC 2022 Annual Meeting E xpression of gp100 protein , the target of KIMMTRAK, is unchange...

Medison Pharma said South and Central Americas and the Caribbean markets (Latin America) were added to its multi-territorial agreement with Immunocore ( NASDAQ: IMCR ). Immunocore's drug Kimmtrak is approved to treat a type of eye cancer called uveal melanoma in the U....

Immunocore press release ( NASDAQ: IMCR ): Q3 GAAP EPS of $0.13 beats by $0.44 . Revenue of $45.87M (+474.8% Y/Y) beats by $11.15M . For further details see: Immunocore GAAP EPS of $0.13 beats by $0.44, revenue of $45.87M beats by $11.15M

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy targe...